Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Unexpected bleeding disorders: Algorithm for approach to therapy.

J M Teitel1

  • 1St. Michael's Hospital Toronto, Ontario, Canada.

Clinical and Laboratory Haematology
|March 17, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anticoagulant therapy.

Canadian family physician Medecin de famille canadien·2011
Same author

Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care.

Haemophilia : the official journal of the World Federation of Hemophilia·2008
Same author

A review of research related to blood transfusion in Canada, 2000-2002.

Transfusion medicine (Oxford, England)·2004
Same author

Home management of haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2004
Same author

Discrepancies in measured factor VIII activity in patients treated with factor VIII concentrate of human or porcine origin.

Thrombosis and haemostasis·2002
Same author

Health-related quality-of-life treatments for severe haemophilia: utility measurements using the Standard Gamble technique.

Haemophilia : the official journal of the World Federation of Hemophilia·2002
Same journal

Cystic fibrosis presenting with haematological abnormalities.

Clinical and laboratory haematology·2006
Same journal

T-cell-rich B-cell lymphoma of the spleen presenting with severe hypersplenism.

Clinical and laboratory haematology·2006
Same journal

Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support.

Clinical and laboratory haematology·2006
Same journal

Analysis of the CDR3 region of alpha/beta T-cell receptors (TCRs) and TCR BD gene double-stranded recombination signal sequence breaks end in peripheral blood mononuclear cells of T-lineage acute lymphoblastic leukemia.

Clinical and laboratory haematology·2006
Same journal

Characterization of several amino acid transports and glutamine metabolism in MOLT4 human T4 leukemia cells.

Clinical and laboratory haematology·2006
Same journal

Osteomylelitis and necrosis of the jaw in patients treated with bisphosphonates: a comparative study focused on multiple myeloma.

Clinical and laboratory haematology·2006
See all related articles

Managing unexpected bleeding requires tailored treatments based on specific causes, as no single product works for all. Pharmaceutical approaches are preferred to minimize risks associated with plasma products.

Area of Science:

  • Hematology
  • Pharmacology
  • Critical Care Medicine

Background:

  • Unexpected bleeding necessitates targeted management strategies due to the absence of a universal procoagulant.
  • Pharmaceutical interventions offer a safer alternative to plasma-derived products, mitigating associated risks.

Purpose of the Study:

  • To outline a practical, algorithmic approach for managing unexpected bleeding.
  • To discuss the use of specific procoagulant products, including desmopressin, factor concentrates, and recombinant agents.
  • To highlight the role of ancillary methods and addressing the underlying cause of bleeding.

Main Methods:

  • Review of current therapeutic options for managing bleeding disorders.
  • Discussion of pharmaceutical agents, replacement therapies (including recombinant proteins), and ancillary measures.

Related Experiment Videos

  • Emphasis on algorithmic decision-making based on patient stability and bleeding characteristics.

    • Main Results:

    • Desmopressin is effective for mild hemophilia A, von Willebrand's disease, and some platelet disorders.
    • Replacement therapy should be specific, utilizing purified components or recombinant proteins for enhanced safety.
    • Bypass therapies like activated prothrombin complex concentrates or recombinant activated factor VIIa are options for inhibitor patients.
    • Ancillary methods (antifibrinolytics, corticosteroids, topical agents, physical measures) and addressing the inciting cause are crucial.

    Conclusions:

    • Effective bleeding management hinges on identifying the specific hemostatic defect and tailoring treatment accordingly.
    • A stepwise approach, considering patient stability and the nature of the bleed, is essential.
    • Pharmaceutical and recombinant therapies, alongside ancillary measures and etiological management, form the cornerstone of hemostasis control.